Influence on liver function of hepatic artery interventional chemoembolization combined reduced glutathione therapy for elderly patients with advanced liver cancer

Objective:To explore the influence on liver function of hepatic artery interventional chemoembolization combined reduced glutathione therapy for elderly patients with advanced liver cancer.Methods:A total of 120 cases of elderly patients with advanced liver cancer from digestive surgery in-patient department of our hospital during the period of January 2014 and January 2016 were selected as the research object, the patients were divided into two groups by using the random number table method,each for 60 cases.The control group were given conventional drugs chemotherapy, the study group were given hepatic artery interventional chemoembolization combined reduced glutathione therapy, serum liver function indexes of Direct Bilirubin(DBil), Total Bilirubin(TBil), Aspartate Transaminase(AST) and Alanineamino Transferase (ALT)were detected by using automatic biochemical analyzer. Results: The clinical remission rate of study group was significantly higher than the control group, the recurrence rate was obviously lower than the control group,compared between the two groups with statistically significant differences. The average survival time of study group (29.36±6.25) months, was significantly longer than the control group (18.02±4.16) months .Before the treatment, serum DBil, TBil, AST and ALT levels compared between the two groups with no statistically significant differences,after the treatment,the indexes of study group was significantly lower than the control group. The indexes levels compared between pre-therapy and post-therapy in study group with no statistically significant differences, while the indexes levels of post-therapy in the control group were significantly higher than those pre-therapy. Before the treatment, the life quality score compared between the two groups with no statistically significant differences, after treatment,the score of all patients were significantly higher than those pre-therapywhich the score of study group was significantly higher than the control group.The incidence rate of drug adverse reactions compared between the two groups with no statistically significant differences.Conclusion: The clinical efficacy of hepatic artery interventional chemoembolization combined reduced glutathione therapy for elderly patients with advanced liver cancer is satisfying, and helps to significantly improve liver function, improve life quality, it is worth popularization and application in the clinical practice.

Decision-Making Process for the Place of Death of Elderly Patients with Advanced Cancer and Their Families

Purpose: This study aims to understand how elderly patients with advanced cancer and their families make a decision for a place of death for the patient. Methods: Semi-structured interviews were conducted with 17 pairs of elderly patients and members of their family. The patients had finished anticancer treatment and made some decision about the preferred place of death. A modified grounded-theory approach was used for the data analysis. Results: Making a “tentative” decision for the place of death of the elderly patients is a process with the core category [carefully choosing the final place for self-fulfillment]. The patients were “conducting a comprehensive review of the place of death” and “embracing the wishes for a way of life without difficulty”. Involving the family in making a “tentative” decision about the place of death of the elderly patients is the process with the core category [realizing the wish of patients in the terminal condition for the way for death]. The families were “examining the place of death from different aspects” and “respecting the patient’s intention as far as possible”. Conclusions: When the patients [carefully choosing the final place for self-fulfillment], it was important to reconcile their wishes with the burden on the families. When the families were trying to [realize the wish of patients in the terminal condition for the way for dying], it was important to balance the respect for the patient intentions and homecare they can provide for the patient. For the patients and their families, it is essential to mutually understand the intentions and wishes of the other party in decision making about the place of death.

Primary liver cancer in the elderly: report of 125 cases

OBJECTIVES: To understand the characteristics of primary, liver camcer (PLC) in the elderly and summarize the experience in treatment of such patients. METHODS: The clinical data of PLC in the elderly group (≥60 years, 125 patients) and the young group (≤59 years, 295 patients) were analyzed retrospectively. RESULTS: In the elderly group, 64 patients were found HBsAg positive, 39 patients small PLC, 24 large PLC, 15 tumor emboli in the portal vein, 86 AFP positive, and 34 hepatectomy performed. In the young group, 205 patients were found HBsAg positive, 79 patients small PLC, 97 large PLC, 96 tumor emboli in the portal vein, 200 AFP positive, and 126 hepatectomy performed. The median survival was 44 and 25 months respectively, and no significant difference was observed in the mortality between the two groups (P>0.05). CONCLUSIONS: Hepatectomy is a choice of treatment for PLC in the elderly based on their liver function. AFP and B-ultrasonography are important methods for the diagnosis of PLC in the elderly.

Clinical observation of docetaxel in treating advanced non-small cell lung cancer in the elderly patients

Objective:The aim of our study was to evaluate the clinical efficacy and side effects of docetaxel as single chemotherapy for elderly patients with advanced non-small-cell lung cancer (NSCLC). Methods: Forty-two elderly patients with advanced NSCLC who were chemotherapy-naive were enrolled in this study. Docetaxel at the doses of 70 mg/m2 was administrated intravenously every 21 days as a cycle, each patient received 2-4 cycles. All patients were followed up until disease progressed or patients died. Results: Among 42 patients, 40 could be evaluated, 1 complete response (CR), 9 partial response (PR), 13 stable disease (SD), 17 progress disease (PD). The overall response rate (CR+PR) was 35% and disease control rate (CR+PR+SD) was 57.5%. The median time to progress (TTP) was 4.2 months, median survival time was 6.1 months and 1-year survival rate was 35.8%. The main toxicity was myelosuppression and decreasing platelet. Conclusion: Single agent docetaxel for elderly patients with advanced NSCLC is an efficient and well-tolerated chemotherapeutic approach with a low toxicity level.

Effect of kanglaite injection and docetaxel in treating advanced stage esophageal cancer on tumor markers, angiogenesis and immune function in elderly patients

Objective:To investigate the effect of Kanglaite injection combined with docetaxel in advanced esophageal cancer on tumor markers, angiogenesis and immune function in elderly patients.Method:A total of 130 patients with advanced esophageal cancer admitted in our hospital from October 2014 to July 2017were selected and divided into two groups according to the time of admission, 65 cases in each group, set as observation group and control group, all patients were treated with conventional radiotherapy (cisplatin combined with 5-fluorouracil), the observation group was given Kanglaite injection combined with docetaxel on the basis of this, while the control group only was given docetaxel treatment, the treatment period was 6 weeks, tumor markers, VEGF and immune function of both group after treatment were compared.Result: After treatment, the levels of carbohydrate antigen 125 (CA125), carbohydrate antigen 19-9 (CA19-9) and carcino-embryonic antigen (CEA) in the observation group were lower than those in the control group, the difference was statistically significant;VEGF level in the observation group after treatment was lower than the control group, the difference was statistically significant;After treatment, the levels of CD3+, CD4+ and CD4+/CD8+ in the observation group were higher than those in the control group, while the levels of CD8+ in the observation group was lower than those in the control group, the difference was statistically significant.Conclusion: Kanglaite injection combined with docetaxel in the treatment of elderly patients with advanced esophageal cancer is better, effectively reducing the level of tumor markers and vascular endothelial growth factor, improve immune function, it isworthy of clinical application.

Clinical Application and Research Progress of Accelerated Rehabilitation Surgery in Perioperative Period of Advanced Gastric Cancer in the Elderly

Enhanced recovery after surgery (ERAS) has been used in various surgical professions in recent years and is widely accepted by doctors. This concept not only helps patients speed up postoperative recovery, reduce the incidence of related complications and shorten hospital stays, but also has been proved to be effective and safe in the perioperative application of gastric cancer. This article reviews the clinical application and research progress of enhanced recovery after surgery in the perioperative period of advanced gastric cancer in the elderly.

Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients

Although it is assumed that the combination of chemotherapy and radical surgery should be indicated in all newly diagnosed advanced-stage ovarian cancer patients, one of the main raised questions is how to select the best strategy of initial treatment in this group of patients, neoadjuvant chemotherapy followed by interval debulking surgery or primary debulking surgery followed by adjuvant chemotherapy. The selection criteria to offer one strategy over the other as well as a stepwise patient selection for initial treatment are described. Selecting the best strategy of treatment in newly diagnosed advanced stage ovarian cancer patients is a multifactorial and multidisciplinary decision. Several factors should be taken into consideration:(1) the disease factor, related to the extension and localization of the disease as well as tumor biology;(2) the patient factor, associated with patient age, poor performance status, and co-morbidities; and(3) institutional infrastructure factor, related to the lack of prolonged operative time, an appropriate surgical armamentarium, as well as well-equipped intensive care units with well-trained personnel.

Morbidity and mortality of elderly patients with advanced gastric cancer after laparoscopy-assisted or open distal gastrectomy:a randomized–controlled trial

Laparoscopy-assisted distal gastrectomy(LDG)combined with D2 lymphadenectomy may be safely performed in patients with advanced gastric cancer(AGC)by experienced surgeons at specialized high-volume institutions as shown in the Chinese Laparoscopic Gastrointestinal Surgery Study(CLASS)-01.However,studies focusing on the use of LDG in patients with gastric cancer older than 65 years are rare.This study was designed to investigate the morbidity and mortality of elderly patients with gastric cancer who underwent laparoscopic-assisted or open distal gastrectomy(ODG).In this prospective,randomized,open,parallel controlled trial,patients older than 65 years with tumor located at the middle or lower part of the stomach will be enrolled in this study.Patients will be randomly divided into a laparoscopic group and an open surgery group.The early post-operative complications,intra-operative complications and post-operative recovery will be compared between the two groups.This trial will provide valuable clinical evidence for the objective assessment of the feasibility,short-term safety,and potential benefits of LDG compared with ODG for gastric cancer in the elderly patients.This trial has been registered on ClinicalTrials.gov.(Identifier:NCT02246153.)in September 22,2014.

Bevacizumab in combination with pemetrexed and platinum for elderly patients with advanced non-squamous non-small-cell lung cancer:a retrospective analysis

Bevacizumab,an anti-VEGF monoclonal antibody,has significantly improved the clinical outcomes of patients with advanced non-squamous NSCLC(ns-NSCLC).However,the safety and efficacy of bevacizumab for elderly patients with advanced NSCLC require further investigation.Thus,59 patients were included in the present retrospective study,22 patients in the bevacizumab plus pemetrexed and platinum(B+PP)group,and 37 patients in the pemetrexed and platinum(PP)group.For the entire cohort of patients,the median OS was 33.3 months,and the 1-year and 2-year overall survival rates were 88.5%and 67.8%,respectively.The median OS and 1-year and 2-year OS rates were 20.5 months,70.3%and 0%,respectively,in the B+PP group and 33.4 months,97.0%and 89.4%,respectively,in the PP group(P<0.001).The incidence of grade≥3 adverse events was higher in the B+PP group than in the PP group(27.3%vs.10.8%,respectively;P=0.204).Univariate and multivariate analyses suggested that the receipt of≥5 cycles of first-line chemotherapy was an independent favorable prognostic factor for OS,whereas the addition of bevacizumab was an unfavorable prognostic factor.With increased toxicities,the addition of bevacizumab to PP does not improve the overall survival of elderly patients with advanced ns-NSCLC.

An Elderly Patient with Advanced Lung Cancer Achieved Long-Term Survival Using Chinese Medicine:An Alternative Treatment Strategy for Cancer Patients Aged 80 or Older without A Tissue Confirmed Diagnosis

Lung cancer is the leading cause of cancerrelated mortality in China.（1＇2） Meanwhile, the average life expectancy in the aging population has increased from 46 years in 1950 to 75 years in 2010.

Role of cetuximab in first-line treatment of metastatic colorectal cancer

The treatment of metastatic colorectal cancer(mCRC)has evolved considerably in the last decade,currently allowing most mCRC patients to live more than two years.Monoclonal antibodies targeting the epidermal growth factor receptor(EGFR)and vascular endothelial growth factor play an important role in the current treatment of these patients.However,only antibodies directed against EGFR have a predictive marker of response,which is the mutation status of v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog(KRAS).Cetuximab has been shown to be effective in patients with KRAS wild-type mCRC.The CRYSTAL study showed that adding cetuximab to FOLFIRI(regimen of irinotecan,infusional fluorouracil and leucovorin)significantly improved results in the first-line treatment of KRAS wildtype mCRC.However,results that evaluate the efficacy of cetuximab in combination with oxaliplatin-based chemotherapy in this setting are contradictory.On the other hand,recent advances in the management of colorectal liver metastases have improved survival in these patients.Adding cetuximab to standard chemotherapy increases the response rate in patients with wild-type KRAS and can thus increase the resectability rate of liver metastases in this group of patients.In this paper we review the different studies assessing the efficacy of cetuximab in the first-line treatment of mCRC.

甲磺酸阿帕替尼联合经导管动脉化疗栓塞术对晚期原发性肝癌患者免疫功能及甲胎蛋白水平的影响

目的探讨甲磺酸阿帕替尼联合经导管动脉化疗栓塞术(TACE)对晚期原发性肝癌患者免疫功能及甲胎蛋白水平的影响。方法选取2021年6月至2022年7月于九江市第一人民医院入院就诊的62例晚期原发性肝癌患者作为研究对象,按照随机数字表法分为对照组与观察组,每组31例。对照组给予单一TACE治疗,观察组给予甲磺酸阿帕替尼联合TACE治疗。比较两组临床疗效、免疫功能指标、甲胎蛋白水平、辅助性T细胞(Th)1型细胞因子水平、不良反应发生情况。结果观察组治疗总有效率高于对照组,差异有统计学意义(P<0.05)。治疗后,观察组CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于对照组,CD8^(+)水平低于对照组,差异有统计学意义(P<0.05)。治疗后3、6个月,观察组甲胎蛋白水平均低于对照组,差异有统计学意义(P<0.05)。观察组白细胞介素-12(IL-12)、干扰素-γ(INF-γ)、肿瘤坏死因子-α(TNF-α)均水平低于对照组,差异有统计学意义(P<0.05)。观察组不良反应发生率低于对照组,差异有统计学意义(P<0.05)。结论甲磺酸阿帕替尼联合TACE治疗晚期原发性肝癌可有效改善者免疫功能,降低甲胎蛋白水平,临床疗效显著且安全性好,具有较高的临床应用价值。

基于既病防变思想的健脾行气解毒法治疗中晚期原发性肝癌患者的效果

目的研究基于既病防变思想的健脾行气解毒法对中晚期原发性肝癌患者的作用效果。方法选取安阳市中医院2019年4月至2023年4月收治的80例中晚期原发性肝癌患者,随机分为对照组和观察组,对照组(40例)接受索拉非尼联合放疗,观察组(40例)联合基于既病防变思想的健脾行气解毒法治疗,对比两组中医证候积分、肝功能、肿瘤标志物水平、复发转移情况和不良反应发生率。结果治疗后,观察组谷草转氨酶(GOT)、谷丙转氨酶(GPT)、总胆红素(TBil)、细胞角蛋白19片段抗原21-1(CYFRA21-1)、甲胎蛋白(AFP)、糖类抗原199(CA199)水平均低于对照组(P<0.05),肿瘤复发转移率及中医证候积分低于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论基于既病防变思想的健脾行气解毒法治疗中晚期原发性肝癌患者的效果确切,能够降低中医证候积分,改善肝功能,降低肿瘤标志物水平和肿瘤复发转移率,安全性高,具有临床推广价值。

程序性细胞死亡蛋白-1抑制剂联合仑伐替尼对老年中晚期原发性肝癌患者免疫功能及生存期的影响

目的探究程序性细胞死亡蛋白-1(programmed death-1,PD-1)抑制剂联合仑伐替尼对老年中晚期原发性肝癌患者免疫功能及生存期的影响。方法选取2021年1月至2022年5月中国人民解放军联勤保障部队第九O八医院收治的84例老年中晚期原发性肝癌患者作为研究对象,随机分为A组与B组,每组42例。A组应用仑伐替尼治疗,B组应用仑伐替尼联合PD-1抑制剂治疗。比较两组临床疗效、治疗前后免疫细胞水平、血清细胞因子、肝功能指标、中位生存期及毒性反应。结果B组客观缓解率、局部控制率均高于A组,差异有统计学意义(P<0.05);治疗后,B组CD3^(+)、CD4^(+)水平及CD4^(+)/CD8^(+)均高于A组,血管内皮生长因子、碱性成纤维细胞生长因子、丙氨酸转氨酶、天冬氨酸转氨酶、总胆红素水平均低于A组,差异有统计学意义(P<0.05);B组中位疾病进展时间长于A组,差异有统计学意义(P<0.05);两组毒性反应总发生率比较差异无统计学意义。结论PD-1抑制剂联合仑伐替尼治疗老年中晚期原发性肝癌患者疗效显著,延长患者生存期,安全性良好,值得临床推广应用。

基于多学科协作的预见性护理干预在原发性肝癌化疗患者中的应用研究

目的分析基于多学科协作(MDT)的预见性护理干预在原发性肝癌(PLC)化疗患者中的应用效果。方法选择2021年1月至2023年4月我院诊治的200例PLC化疗患者,均开展肝动脉栓塞化疗术(TAcE)治疗,采用随机数字表将患者分为MDT组(采用MDT干预,n=66)、预见性护理组(采用预见性护理,n=66)及联合护理组(基于MDT的预见性护理,n=68),记录三组患者疼痛情况[简化麦吉尔疼痛(SF-MPQ)]、睡眠质量[总体睡眠障碍(GSDS)]、治疗依从性[治疗依从性量表(ARS)]、生活质量[癌症患者生命质量测定量表(QLQC-30)]、疲劳评分[疲劳评定量表(FAS)]、以及并发症情况。结果护理后三组SF-MPQ、GSDS、ARS及FAS评分均明显降低,其中联合护理组各项评分显著低于MDT组与预见性护理组(P<0.05);三组QLQC-30评分明显升高,且联合护理组>MDT组>预见性护理组(P<0.05);联合护理组并发症总发生率(2.94%)显著低于MDT组(15.15%)与预见性护理组(12.12%),差异有统计学意义(P<0.05)。结论基于MDT的预见性护理干预对PLC化疗患者的干预效果较好,可促进患者机体恢复效果,进一步减少并发症发的发生,强化机体健康状态,促进其恢复,可推广应用。

改良版患者主观整体评估可用于原发性肝癌患者营养不良的评估

目的研究原发性肝癌患者的营养状况,比较患者主观整体评估(PG-SGA)和改良版患者主观整体评估(mPG-SGA)评估营养不良的能力。方法纳入2022年4月至2023年9月于西南医科大学附属医院首诊为原发性肝癌的249例患者,采用PG-SGA和m PG-SGA评估患者营养状况,通过Spearman相关分析比较不同营养指标与两种量表评估结果的相关性,绘制受试者操作特征(ROC)曲线评价m PG-SGA的准确性,计算Kappa系数评价两种量表的一致性。结果249例原发性肝癌患者中,PG-SGA和m PG-SGA分别诊断出中、重度营养不良患者196例(78.71%)、189例(75.90%)。以PG-SGA为标准,对于营养良好/轻度营养不良、中度营养不良及重度营养不良3种不同营养状态,mPG-SGA均表现出较好的准确性,AUC值分别为0.982、0.938、0.977(P<0.001),并具有强一致性(Kappa=0.951,P<0.001)。通过性别、年龄、吸烟史、饮酒史、临床分期、体质指数(BMI)分层分析发现,BMI<18.5 kg/m^(2)的患者中,mPG-SGA对营养良好/轻度营养不良、中度营养不良及重度营养不良3种不同营养状态表现出较强的一致性(Kappa=0.762,P=0.001),除外BMI<18.5 kg/m^(2)的其余临床特征分层分析中,mPG-SGA对3种不同营养状态均表现出强一致性(Kappa>0.9,P<0.001)。结论原发性肝癌患者营养不良发生率高,mPG-SGA与PG-SGA具有良好的准确性及一致性,是一种更简便、适用于评估原发性肝癌患者营养不良的工具。

卡瑞利珠单抗联合肝动脉化疗栓塞术治疗中晚期原发性肝癌患者的效果

目的:观察卡瑞利珠单抗联合肝动脉化疗栓塞术(TACE)治疗中晚期原发性肝癌患者的效果。方法:选取2020-2022年该院收治的70例中晚期原发性肝癌患者进行前瞻性研究,采用随机数字表法将其分为对照组和观察组各35例。对照组给予TACE治疗,观察组在对照组基础上联合卡瑞利珠单抗治疗,比较两组临床疗效,治疗前后血清学指标[天冬氨酸氨基转移酶(AST)、丙氨酸氨基转移酶(ALT)、白蛋白(ALB)、总胆红素(TBIL)]、肿瘤标志物[甲胎蛋白(AFP)、癌胚抗原(CEA)、甲胎蛋白异质体L3(AFP-L3)]水平,以及不良反应/并发症发生率。结果:观察组疾病控制率为94.29%(33/35),高于对照组的77.14%(27/35),差异有统计学意义(P<0.05);两组客观缓解率比较,差异无统计学意义(P>0.05);治疗后,观察组AST、ALT、TBIL水平均低于对照组,ALB水平高于对照组,差异有统计学意义(P<0.05);治疗后,观察组AFP、CEA、AFP-L3水平均低于对照组,差异有统计学意义(P<0.05);观察组不良反应/并发症发生率为48.71%(17/35),高于对照组的25.71%(9/35),差异有统计学意义(P<0.05)。结论:卡瑞利珠单抗联合TACE治疗中晚期原发性肝癌患者可提高疾病控制率,改善血清学指标水平,降低肿瘤标志物水平,效果优于单纯TACE治疗,但会增高不良反应/并发症发生率。

人文关怀在原发性肝癌患者护理中的应用与效果

目的探讨人文关怀在原发性肝癌患者护理中的应用与效果。方法 2015年6月至2016年5月,便利抽样法选取在第二军医大学东方肝胆外科医院治的初诊原发性肝癌患者80例为研究对象,按住院时间先后将其分为观察组和对照组,每组各40例。观察组患者给于人文关怀护理,而对照组患者给予常规护理,比较两组患者手术日晨及术后24 h的焦虑评分、治疗配合度、住院舒适度及满意度。结果观察组患者手术日晨及术后24 h的焦虑评分分别为(4.02±1.02)分、(3.02±1.28)分,与对照组[(5.78±1.43)、(5.66±1.11)分]相比,差异均有统计学意义(均P<0.05)。观察组患者满意率为100.0%,高于对照组的87.50%,差异有统计学意义(P<0.05)。两组患者的配合度及住院舒适度的差异有统计学意义(P<0.05)。结论将人文关怀融入到医疗护理工作中,不仅改善了原发性肝癌患者焦虑心理,而且提高了患者对护理工作的满意度。

肝动脉化疗栓塞术中植入氟尿嘧啶、奥沙利铂、吡柔比星治疗中晚期原发性肝癌的临床研究

目的研究肝动脉化疗栓塞术(TACE)中植入氟尿嘧啶、奥沙利铂和吡柔比星治疗中晚期原发性肝癌(PHC)的临床效果。方法选择中晚期PHC患者68例,按照随机数字表法分为联合组与对照组,每组各34例。联合组患者行TACE治疗,术中植入氟尿嘧啶、奥沙利铂和吡柔比星;对照组患者行肝动脉栓塞(TAE)治疗。观察两组治疗前后甲胎蛋白(AFP)、E-钙粘连蛋白(EC)、内皮抑素(E)、VEGF和免疫细胞水平、无进展生存期、总生存期、临床疗效及不良反应。结果治疗后,联合组AFP、EC、E、VEGF水平均低于对照组,差异有统计学意义(P<0.05);联合组CD3+、CD4+、CD4+/CD8+水平均高于对照组,CD8+水平低于对照组,差异均有统计学意义(P<0.05);联合组无进展生存期、中位无进展生存期均高于对照组,差异有统计学意义(P<0.05);除恶心、呕吐外,联合组其他不良反应与对照组比较,差异无统计学意义(P>0.05)。结论 TACE术中植入氟尿嘧啶、吡柔比星及奥沙利铂可有效杀灭肝癌细胞,改善患者免疫水平及远期疗效,减少不良反应。

索拉非尼治疗19例晚期原发性肝癌临床疗效观察

目的：观察索托非尼治疗19例晚期原发性肝癌患者的疗效及不良反应。方法19例无法手术切除的晚期原发性肝癌患者口服索拉非尼400 mg，2次/d，至出现不可耐受的不良反应或连续两次评价为疾病进展时停药，观察疗效和不良反应。结果在服药后3个月观察，获得 PR 1例（5.3%），SD 10例（52.6%），PD8例（42.1%），42.9%（6/14）患者 AFP 明显降低，而50.0%（7/14）呈不同程度的增加；随访3～22（8.5）个月，16例（84.2％）患者死亡，3例（16％）患者仍继续服药，中位疾病进展时间（TTP）为5.1个月（1.5～15.0个月），中位总生存期（OS）为6.5个月（3.0-22.0个月）；16例（84.2％）患者出现手足皮肤硬化、麻木，7例（36.8%）出现皮疹和脱发，10例（52.6%）血压升高，15例（78.9%）发生胃肠道不良反应，2例（10.5%）发生骨髓抑制，8例（42.1%）出现腹泻。结论索拉非尼治疗晚期原发性肝癌患者有一定的疗效，多数不良反应可以耐受，服药期间患者的生活质量保持稳定。